Rising speculation that Eli Lilly could produce its blockbuster weight-loss drug Mounjaro in Korea drove sharp gains in Kosdaq-listed biotech firm Peptron and drew renewed attention to SK Pharmteco on Friday, though the SK subsidiary declined to confirm.
Mounjaro is a treatment for Type 2 diabetes, which is also known to be effective for weight loss.
Continue Reading on The Korea Herald
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.